Literature DB >> 21680866

Do infants increase the risk of re-emergent infection in households after mass drug administration for trachoma?

Sheila K West1, Dianne Stare, Harran Mkocha, Beatriz Munoz, Charlotte Gaydos, Thomas C Quinn.   

Abstract

PURPOSE: Mass treatment with azithromycin for trachoma endemic communities typically excludes infants under age 6 months, whose parents are provided with tubes of tetracycline to administer daily over 4 to 6 weeks. The authors sought to determine whether infants aged <6 months are a source of re-emergent infection in their families after mass treatment in trachoma-endemic communities.
METHODS: In a longitudinal study of all children aged less than 10 years in four communities, the authors identified 91 infants aged <6 months living in 86 of 1241 households. All children aged <ten years in all households were examined for trachoma and ocular infection with C. trachomatis at baseline, and 6 months after mass drug administration.
RESULTS: The prevalence of infection at baseline in the infants was 5.9%. At 6 months post mass drug administration, the rate of infection among children older than 6 months and less than 10 years who resided in households with infants was 6.0% compared with 11.1% in children in households without infants (P = 0.18). After adjustment for age, sex, baseline infection status, and treatment, residing in a household with an infant was not associated with infection at 6 months (odds ratio [95% confidence interval] 0.50 [0.20-1.22]).
CONCLUSIONS: This prospective study did not find evidence that living in a household with an infant increased the risk of infection 6 months post mass drug administration in other children residing in the household.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21680866      PMCID: PMC3176068          DOI: 10.1167/iovs.11-7372

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  7 in total

1.  Design and baseline data of a randomized trial to evaluate coverage and frequency of mass treatment with azithromycin: the Partnership for Rapid Elimination of Trachoma (PRET) in Tanzania and The Gambia.

Authors:  Dianne Stare; Emma Harding-Esch; Beatriz Munoz; Robin Bailey; David Mabey; Martin Holland; Charlotte Gaydos; Sheila West
Journal:  Ophthalmic Epidemiol       Date:  2011-02       Impact factor: 1.648

Review 2.  Azithromycin for the treatment and control of trachoma.

Authors:  M J Burton; K D Frick; R L Bailey; R J C Bowman
Journal:  Expert Opin Pharmacother       Date:  2002-02       Impact factor: 3.889

3.  A simple system for the assessment of trachoma and its complications.

Authors:  B Thylefors; C R Dawson; B R Jones; S K West; H R Taylor
Journal:  Bull World Health Organ       Date:  1987       Impact factor: 9.408

Review 4.  Antibiotics for trachoma.

Authors:  D Mabey; N Fraser-Hurt; C Powell
Journal:  Cochrane Database Syst Rev       Date:  2005-04-18

5.  Mass treatment with single-dose azithromycin for trachoma.

Authors:  Anthony W Solomon; Martin J Holland; Neal D E Alexander; Patrick A Massae; Aura Aguirre; Angels Natividad-Sancho; Sandra Molina; Salesia Safari; John F Shao; Paul Courtright; Rosanna W Peeling; Sheila K West; Robin L Bailey; Allen Foster; David C W Mabey
Journal:  N Engl J Med       Date:  2004-11-04       Impact factor: 91.245

Review 6.  Trachoma: global magnitude of a preventable cause of blindness.

Authors:  S P Mariotti; D Pascolini; J Rose-Nussbaumer
Journal:  Br J Ophthalmol       Date:  2008-12-19       Impact factor: 4.638

7.  Mass treatment and the effect on the load of Chlamydia trachomatis infection in a trachoma-hyperendemic community.

Authors:  Emily S West; Beatriz Munoz; Harran Mkocha; Martin J Holland; Aura Aguirre; Anthony W Solomon; Robin Bailey; Allen Foster; David Mabey; Sheila K West
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-01       Impact factor: 4.799

  7 in total
  7 in total

1.  Risk of Infection with Chlamydia trachomatis from Migrants to Communities Undergoing Mass Drug Administration for Trachoma Control.

Authors:  Sheila K West; Beatriz E Munoz; Harran Mkocha; Charlotte Gaydos; Thomas Quinn
Journal:  Ophthalmic Epidemiol       Date:  2015       Impact factor: 1.648

2.  Geospatial distribution and clustering of Chlamydia trachomatis in communities undergoing mass azithromycin treatment.

Authors:  Jithin Yohannan; Bing He; Jiangxia Wang; Gregory Greene; Yvette Schein; Harran Mkocha; Beatriz Munoz; Thomas C Quinn; Charlotte Gaydos; Sheila K West
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-06-06       Impact factor: 4.799

Review 3.  Trachoma: an update on prevention, diagnosis, and treatment.

Authors:  Satasuk Joy Bhosai; Robin L Bailey; Bruce D Gaynor; Thomas M Lietman
Journal:  Curr Opin Ophthalmol       Date:  2012-07       Impact factor: 3.761

4.  Treating village newcomers and travelers for trachoma: Results from ASANTE cluster randomized trial.

Authors:  Sheila K West; Beatriz Munoz; Harran Mkocha; Laura Dize; Charlotte A Gaydos; Bonnie Swenor; Ann-Margret Ervin; Thomas C Quinn
Journal:  PLoS One       Date:  2017-06-29       Impact factor: 3.240

Review 5.  The Relationship between Active Trachoma and Ocular Chlamydia trachomatis Infection before and after Mass Antibiotic Treatment.

Authors:  Athumani M Ramadhani; Tamsyn Derrick; David Macleod; Martin J Holland; Matthew J Burton
Journal:  PLoS Negl Trop Dis       Date:  2016-10-26

6.  Safety of azithromycin in infants under six months of age in Niger: A community randomized trial.

Authors:  Catherine E Oldenburg; Ahmed M Arzika; Ramatou Maliki; Mohamed Salissou Kane; Elodie Lebas; Kathryn J Ray; Catherine Cook; Sun Y Cotter; Zhaoxia Zhou; Sheila K West; Robin Bailey; Travis C Porco; Jeremy D Keenan; Thomas M Lietman
Journal:  PLoS Negl Trop Dis       Date:  2018-11-12

7.  Population-Based Prevalence of Ocular Chlamydia trachomatis Infection among Infants in the Trachoma Endemic Amhara Region, Ethiopia.

Authors:  Scott D Nash; Ambahun Chernet; Tigist Astale; Eshetu Sata; Mulat Zerihun; Andrew W Nute; Kimberly A Jensen; Demelash Gessese; Zebene Ayele; Berhanu Melak; Mahteme Haile; Taye Zeru; Zerihun Tadesse; E Kelly Callahan
Journal:  Am J Trop Med Hyg       Date:  2021-10-25       Impact factor: 3.707

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.